CA2684059C - Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions - Google Patents

Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions Download PDF

Info

Publication number
CA2684059C
CA2684059C CA2684059A CA2684059A CA2684059C CA 2684059 C CA2684059 C CA 2684059C CA 2684059 A CA2684059 A CA 2684059A CA 2684059 A CA2684059 A CA 2684059A CA 2684059 C CA2684059 C CA 2684059C
Authority
CA
Canada
Prior art keywords
antagonist
agonist
addictive
opioid
addiction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2684059A
Other languages
English (en)
French (fr)
Other versions
CA2684059A1 (en
Inventor
Roberto Ciccocioppo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Publication of CA2684059A1 publication Critical patent/CA2684059A1/en
Application granted granted Critical
Publication of CA2684059C publication Critical patent/CA2684059C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2684059A 2007-04-11 2008-04-11 Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions Active CA2684059C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91120107P 2007-04-11 2007-04-11
US60/911,201 2007-04-11
PCT/US2008/060146 WO2008128126A1 (en) 2007-04-11 2008-04-11 Compositions and methods for prophylaxis and treatment of addictions

Publications (2)

Publication Number Publication Date
CA2684059A1 CA2684059A1 (en) 2008-10-23
CA2684059C true CA2684059C (en) 2016-07-12

Family

ID=39864359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2684059A Active CA2684059C (en) 2007-04-11 2008-04-11 Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions

Country Status (13)

Country Link
US (1) US8426439B2 (https=)
EP (4) EP3788877B1 (https=)
JP (2) JP5548120B2 (https=)
KR (1) KR101622403B1 (https=)
CN (3) CN101711107A (https=)
AU (1) AU2008240158B2 (https=)
BR (1) BRPI0810525B8 (https=)
CA (1) CA2684059C (https=)
ES (4) ES2586433T3 (https=)
MX (2) MX356965B (https=)
NZ (1) NZ580963A (https=)
RU (1) RU2492858C2 (https=)
WO (1) WO2008128126A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
AU2013202267B2 (en) * 2007-04-11 2015-03-19 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009158120A2 (en) * 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
CN102348457A (zh) * 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
DK2846805T3 (en) * 2012-05-07 2019-03-18 Omeros Corp TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS
SI2846805T1 (sl) * 2012-05-07 2019-04-30 Omeros Corporation Zdravljenje zasvojenosti in motenj v obvladovanju impulzov z uporabo inhibitorjev PDE7
CA2878402A1 (en) * 2012-07-06 2014-01-09 Omeros Corporation Andrographis paniculata compositions and methods for treatment of addictions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015023871A1 (en) * 2013-08-15 2015-02-19 Medicinova, Inc. Treatment of alcoholism using ibudilast
US20170173039A1 (en) * 2014-04-02 2017-06-22 Yale University Compositions and methods to treat addiction
WO2016065177A1 (en) * 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
KR101960262B1 (ko) * 2016-04-08 2019-03-21 공주대학교 산학협력단 전자 담배 조성물 내 담배 특이 니트로스아민류 및 카르보닐 화합물을 제거 및 생성의 억제, 전자 담배 조성물 흡연 시 발생하는 카르보닐 화합물 제거, 및 니코틴액의 갈변을 막기 위한 전자 담배 니코틴액용 첨가제 및 이를 포함하는 전자 담배 조성물
WO2018204689A1 (en) * 2017-05-04 2018-11-08 The Board Of Regents Of The University Of Texas System Methods of treating synthetic cannabinoid toxicity or overdose with rimonabant
KR102208012B1 (ko) * 2017-12-20 2021-01-27 가톨릭대학교 산학협력단 코카인 중독 특이적 바이오 마커
EP3834888A4 (en) * 2018-08-10 2022-05-11 Servicio Andaluz De Salud MEANS OF TREATMENT OF ALCOHOL ABUSE
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms
CN112569237B (zh) * 2019-09-30 2022-12-02 武汉大学 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788207A (en) 1972-05-26 1974-01-29 Doherty Silentaire Top discharge roof ventilator
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2749583B1 (fr) 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US20040028735A1 (en) 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
WO2000073791A1 (fr) 1999-05-27 2000-12-07 Tanabe Seiyaku Co., Ltd. Remedes pour affections renales et procede de criblage de tels medicaments
US6582738B2 (en) 1999-09-13 2003-06-24 Deseret Laboratories, Inc. Process for preparing chewing gum containing a nutritional supplement
IL148903A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
JP2003510325A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
AU2001247233A1 (en) 2000-02-24 2001-09-03 San Diego State University Ppar gamma agonists for the treatment of liver inflammatory disorders
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
CA2424770A1 (en) 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
GB0030845D0 (en) 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
WO2003016265A1 (en) 2001-08-17 2003-02-27 Eisai Co., Ltd. Cyclic compound and ppar agonist
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
CN1599602A (zh) 2001-10-11 2005-03-23 钟渊化学工业株式会社 过氧化物酶体增殖剂应答性受体配体剂及其制备方法
US20110105748A1 (en) 2001-10-16 2011-05-05 Debnath Bhuniya Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
IL161717A0 (en) 2001-11-26 2004-09-27 Schering Corp Piperidine-based mch antagonists for treatment of obesity and cns disorders
AU2002348829A1 (en) 2001-12-21 2003-07-09 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US7297715B2 (en) 2002-07-30 2007-11-20 Merck & Co., Inc. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003256419A1 (en) 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
JP2007504285A (ja) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
HUE036646T2 (hu) 2003-01-23 2018-07-30 Esperion Therapeutics Inc Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
WO2004092417A2 (en) 2003-04-07 2004-10-28 Emory University Molecular correlates of cocaine addiction and methods for their use
JPWO2004093910A1 (ja) 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
US20050004179A1 (en) 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US7276608B2 (en) 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
AU2004272007B2 (en) 2003-09-10 2009-05-28 Merck Sharp & Dohme Corp. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
EP1696925A4 (en) 2003-10-31 2009-11-18 Merck & Co Inc 21-Heterocyclic 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
NZ547752A (en) 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
TW200528455A (en) 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
RU2006126122A (ru) 2003-12-19 2008-01-27 Бристол-Маерс Сквибб Компани (Us) Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
DK1697371T3 (da) 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
ATE440085T1 (de) * 2004-02-20 2009-09-15 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
EP1735287A1 (en) 2004-04-03 2006-12-27 Astrazeneca AB Therapeutic agents
BRPI0506807A (pt) 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
MXPA06012679A (es) 2004-05-06 2007-01-16 Galderma Res & Dev Nuevos compuestos biaromaticos que activan receptores tipo ppar (gama), procedimiento de preparacion y uso en composiciones cosmeticas o farmaceuticas.
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
DE102004038270A1 (de) 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1776121A2 (en) * 2004-08-13 2007-04-25 Omeros Corporation Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
JP2006065511A (ja) 2004-08-25 2006-03-09 Fujitsu Ltd 閲覧履歴提示システム
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
GT200500246A (es) * 2004-09-09 2006-04-17 Combinacion de compuestos organicos
US20080045580A1 (en) 2004-10-11 2008-02-21 Dr Reddy's Laboratories Limited Novel Isoxazole Compounds Having Ppar Agonist Activity
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
CN101098690A (zh) 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060270722A1 (en) 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
CN101395164A (zh) 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
US20070232573A1 (en) 2006-03-06 2007-10-04 Avestha Gengraine Technologies Pvt. Ltd. Ethanoic acid derivatives as dipeptidyl peptidase inhibitors
KR101333089B1 (ko) 2006-05-22 2013-11-27 재단법인 아산사회복지재단 로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
EP1867994B1 (en) 2006-06-13 2012-09-26 Euroscreen S.A. Ligand for G-protein coupled receptor GPR72 and uses thereof
CA2589393C (en) 2006-06-13 2016-04-12 Euroscreen S.A. Ligand for g-protein coupled receptor gpr72 and uses thereof
JP2008044932A (ja) 2006-07-21 2008-02-28 Daiichi Sankyo Co Ltd チアゾリジンジオン化合物を含有する組成物
US9308198B2 (en) * 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Also Published As

Publication number Publication date
EP2612553B1 (en) 2016-06-08
CN105250285B (zh) 2019-09-06
EP2612553A1 (en) 2013-07-10
JP5548120B2 (ja) 2014-07-16
CN110403942A (zh) 2019-11-05
WO2008128126A1 (en) 2008-10-23
KR101622403B1 (ko) 2016-05-31
RU2009141615A (ru) 2011-05-20
JP2010523718A (ja) 2010-07-15
BRPI0810525B8 (pt) 2021-05-25
KR20090130125A (ko) 2009-12-17
AU2008240158A1 (en) 2008-10-23
MX356965B (es) 2018-06-21
CN101711107A (zh) 2010-05-19
EP3788877A1 (en) 2021-03-10
EP2141989A4 (en) 2010-07-14
ES2438768T3 (es) 2014-01-20
AU2008240158B2 (en) 2014-07-10
EP3053440B1 (en) 2020-08-12
EP3053440A1 (en) 2016-08-10
CA2684059A1 (en) 2008-10-23
JP6010572B2 (ja) 2016-10-19
CN105250285A (zh) 2016-01-20
BRPI0810525B1 (pt) 2021-05-11
RU2492858C2 (ru) 2013-09-20
NZ580963A (en) 2012-08-31
US20090048232A1 (en) 2009-02-19
EP2141989A1 (en) 2010-01-13
JP2014139213A (ja) 2014-07-31
ES2830073T3 (es) 2021-06-02
ES2586433T3 (es) 2016-10-14
EP3788877B1 (en) 2024-08-07
US8426439B2 (en) 2013-04-23
ES2992321T3 (es) 2024-12-11
MX2009010854A (es) 2010-01-28
WO2008128126A8 (en) 2009-01-22
BRPI0810525A2 (pt) 2014-10-07
EP2141989B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
CA2684059C (en) Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions
AU2010224037B2 (en) Compositions and methods for prophylaxis and treatment of addictions
US10064850B2 (en) Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) Compositions and methods for prophylaxis and treatment of addictions
AU2013201888B2 (en) Compositions and methods for prophylaxis and treatment of addictions
AU2013202267B2 (en) Compositions and methods for prophylaxis and treatment of addictions
HK1262395A1 (en) Compositions and methods for prophylaxis and treatment of addictions
HK1227631A1 (en) Compositions and methods for prophylaxis and treatment of addictions
HK1140378A (en) Compositions and methods for prophylaxis and treatment of addictions
HK1140378B (en) Compositions and methods for prophylaxis and treatment of addictions

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404